October 30, 2014—Hospital groups are protesting Genentech’s decision to make them buy three very expensive and much-used cancer drugs exclusively through specialty distributors, saying the change is raising their costs and potentially compromising patient care without enhancing patient safety or supply-chain security.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)